期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 3, 期 6, 页码 341-354出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620712459746
关键词
ruxolitinib; JAKafi; janus kinase 2; myelofibrosis; myeloproliferative neoplasm
类别
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano)
- AGIMM (AIRC - Gruppo Italiano Malattie Mieloproliferative) [1005]
- Leukemia and Lymphoma Fund
- MPD voice
- Novartis
- Shire
Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据